Breast Recurrence Score Test Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
233 Pages
November 2023
Region: Global
Fairfield Market Research
ID: 5910703

The global breast recurrence score test market reported revenue of $250 million in 2024 and is expected to reach a valuation of $510 million by the end of 2031, according to a recent study. The market is driven by the increasing prevalence of breast cancer, technological advancements in multigene assays, and growing awareness of the importance of early cancer recurrence screening.

Key Insights and Market Trends

The Role of 21-Gene Recurrence Score Test

The 21-gene recurrence score test is a crucial tool in predicting distant recurrence risk and guiding adjuvant treatment decisions in early-stage breast cancer patients. It helps tailor treatment plans, reducing the risk of over- or under-treatment, making it a cost-effective alternative to adjuvant chemotherapy.

Rising Breast Cancer Cases

The global burden of breast cancer continues to grow, necessitating effective screening and diagnostic procedures. In some countries, such as India, breast cancer presents more aggressive patterns, emphasizing the need for early recurrence screening and management.

Complex Impact of Patient Age and Hormone Receptor Expression

Patient age and hormone receptor expression can significantly impact the 21-gene recurrence score test results. This complexity underscores the importance of a comprehensive assessment, particularly for women under 50, to ensure accurate treatment decisions.

Country-specific Market Dynamics

United States - Rising Prevalence and Lowering Recurrence Risk

Breast cancer remains the most commonly diagnosed cancer among women in the United States. Advances in hormone therapy and adjuvant therapies have significantly reduced the risk of recurrence, making recurrence score testing crucial in tailoring treatment.

Germany - Favorable Reimbursement Policies

Germany boasts a large cancer patient pool and favorable reimbursement policies for biomarker-based recurrence score tests. Public awareness initiatives and government support contribute to market growth.

India - Aggressive Breast Cancer Patterns

Breast cancer in India tends to be more aggressive, affecting a younger population. The need for early cancer recurrence screening and better access to quality healthcare presents significant growth opportunities for market players.

Competitive Landscape

The breast recurrence score test market features several active players, both local and global. Companies are investing in research and development and expanding their offerings to meet the increasing demand for screening and diagnostic solutions.

Key Companies in the Market

Exact Sciences (Genome Health Inc)
NanoString Technologies, Inc
Foundation Medicine, Inc
ThermoFisher Scientific
Illumina, Inc
Hologic Inc (Biotheranostic)
Biocartis
Roche Diagnostics
Epic Sciences
Qiagen
Abbott
Myriad Genetics, Inc
Guardant Health

Key Segments of Breast Recurrence Score Test Industry Research

Product:

Test Kits
Reagents & Consumables

Indication:

Stage 1 Breast Cancer
Stage 2 Breast Cancer
Estrogen-Receptor-Positive Cancer
Lymph-Node-Negative Cancer

End User:

Hospitals
Specialty Cancer Centers
Diagnostic Centers
Cancer Research Institutions

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Breast Recurrence Score Test Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Breast Recurrence Score Test Market Outlook, 2018 - 2031

3.1. Global Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Test Kits
3.1.1.2. Reagents & Consumables
3.2. Global Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Stage 1 Breast Cancer
3.2.1.2. Stage 2 Breast Cancer
3.2.1.3. Estrogen-Receptor-Positive Cancer
3.2.1.4. Lymph-Node-Negative Cancer
3.3. Global Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Specialty Cancer Centers
3.3.1.3. Diagnostic Centers
3.3.1.4. Cancer Research Institutions
3.4. Global Breast Recurrence Score Test Market Outlook, by Region, Value (US$ Mn) and Volume (Units), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Breast Recurrence Score Test Market Outlook, 2018 - 2031

4.1. North America Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Test Kits
4.1.1.2. Reagents & Consumables
4.2. North America Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Stage 1 Breast Cancer
4.2.1.2. Stage 2 Breast Cancer
4.2.1.3. Estrogen-Receptor-Positive Cancer
4.2.1.4. Lymph-Node-Negative Cancer
4.3. North America Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Specialty Cancer Centers
4.3.1.3. Diagnostic Centers
4.3.1.4. Cancer Research Institutions
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Breast Recurrence Score Test Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.2. U.S. Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.3. U.S. Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.4. U.S. Breast Recurrence Score Test Market by Segment 4, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.5. Canada Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.6. Canada Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.7. Canada Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.1.8. Canada Breast Recurrence Score Test Market by Segment 4, Value (US$ Mn) and Volume (Units), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Breast Recurrence Score Test Market Outlook, 2018 - 2031

5.1. Europe Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Test Kits
5.1.1.2. Reagents & Consumables
5.2. Europe Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Stage 1 Breast Cancer
5.2.1.2. Stage 2 Breast Cancer
5.2.1.3. Estrogen-Receptor-Positive Cancer
5.2.1.4. Lymph-Node-Negative Cancer
5.3. Europe Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Specialty Cancer Centers
5.3.1.3. Diagnostic Centers
5.3.1.4. Cancer Research Institutions
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Breast Recurrence Score Test Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.2. Germany Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.3. Germany Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.4. U.K. Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.5. U.K. Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.6. U.K. Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.7. France Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.8. France Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.9. France Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.10. Italy Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.11. Italy Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.12. Italy Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.13. Turkey Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.14. Turkey Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.15. Turkey Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.16. Russia Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.17. Russia Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.18. Russia Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.19. Rest of Europe Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.20. Rest of Europe Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.1.21. Rest of Europe Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Breast Recurrence Score Test Market Outlook, 2018 - 2031

6.1. Asia Pacific Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Test Kits
6.1.1.2. Reagents & Consumables
6.2. Asia Pacific Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Stage 1 Breast Cancer
6.2.1.2. Stage 2 Breast Cancer
6.2.1.3. Estrogen-Receptor-Positive Cancer
6.2.1.4. Lymph-Node-Negative Cancer
6.3. Asia Pacific Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Specialty Cancer Centers
6.3.1.3. Diagnostic Centers
6.3.1.4. Cancer Research Institutions
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Breast Recurrence Score Test Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.2. China Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.3. China Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.4. Japan Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.5. Japan Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.6. Japan Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.7. South Korea Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.8. South Korea Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.9. South Korea Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.10. India Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.11. India Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.12. India Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.13. Southeast Asia Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.14. Southeast Asia Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.15. Southeast Asia Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Breast Recurrence Score Test Market Outlook, 2018 - 2031

7.1. Latin America Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Test Kits
7.1.1.2. Reagents & Consumables
7.2. Latin America Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.2.1.1. Stage 1 Breast Cancer
7.2.1.2. Stage 2 Breast Cancer
7.2.1.3. Estrogen-Receptor-Positive Cancer
7.2.1.4. Lymph-Node-Negative Cancer
7.3. Latin America Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Specialty Cancer Centers
7.3.1.3. Diagnostic Centers
7.3.1.4. Cancer Research Institutions
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Breast Recurrence Score Test Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.2. Brazil Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.3. Brazil Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.4. Mexico Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.5. Mexico Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.6. Mexico Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.7. Argentina Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.8. Argentina Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.9. Argentina Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.10. Rest of Latin America Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.11. Rest of Latin America Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.1.12. Rest of Latin America Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Breast Recurrence Score Test Market Outlook, 2018 - 2031

8.1. Middle East & Africa Breast Recurrence Score Test Market Outlook, by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Test Kits
8.1.1.2. Reagents & Consumables
8.2. Middle East & Africa Breast Recurrence Score Test Market Outlook, by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Stage 1 Breast Cancer
8.2.1.2. Stage 2 Breast Cancer
8.2.1.3. Estrogen-Receptor-Positive Cancer
8.2.1.4. Lymph-Node-Negative Cancer
8.3. Middle East & Africa Breast Recurrence Score Test Market Outlook, by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Specialty Cancer Centers
8.3.1.3. Diagnostic Centers
8.3.1.4. Cancer Research Institutions
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Breast Recurrence Score Test Market Outlook, by Country, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.2. GCC Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.3. GCC Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.4. South Africa Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.5. South Africa Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.6. South Africa Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.7. Egypt Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.8. Egypt Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.9. Egypt Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.10. Nigeria Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.11. Nigeria Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.12. Nigeria Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Breast Recurrence Score Test Market by Product, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Breast Recurrence Score Test Market by Indication, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Breast Recurrence Score Test Market by End User, Value (US$ Mn) and Volume (Units), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Product vs by Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Exact Sciences (Genome Health Inc.)
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. NanoString Technologies, Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Foundation Medicine, Inc
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. ThermoFisher Scientific
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Illumina, Inc
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Hologic Inc (Biotheranostic)
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Biocartis
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Roche Diagnostics
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Epic Sciences
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Qiagen
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Abbott
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Myriad Genetics, Inc.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Guardant Health
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Exact Sciences (Genome Health Inc.)
NanoString Technologies, Inc.
Foundation Medicine, Inc
ThermoFisher Scientific
Illumina, Inc
Hologic Inc (Biotheranostic)
Biocartis
Roche Diagnostics
Epic Sciences
Qiagen
Abbott
Myriad Genetics, Inc
Guardant Health

Methodology

LOADING...